Premium
Risk‐based decision making and ethical considerations in donor compensation for plasma‐derived medicinal products
Author(s) -
Skinner Mark W.,
Hedlund Hoppe P. Ann,
Grabowski Henry G.,
Manning Richard,
Tachdjian Raffi,
Crone James F.,
Youngner Stuart J.
Publication year - 2016
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.13764
Subject(s) - compensation (psychology) , intensive care medicine , medicine , business , risk analysis (engineering) , psychology , social psychology
F or years, policymakers have debated the appropriateness of compensating plasma donors for the manufacture of plasma-derived medicinal products (PDMPs). Recently, the Alliance of Blood Operators (ABO) developed a risk-based decision-making framework for blood safety. In light of these two parallel discussions, now seems to be an opportune time to reanalyze whether an absolutist position against compensation is any longer relevant or would be appropriate if evaluated utilizing a risk-based decision-making approach. Meeting the health needs of patients by providing an adequate supply of safe and effective blood components and PDMPs is the principal goal of blood operators and the plasma industry. Data demonstrate a large and increasing unmet demand for PDMPs worldwide, and there is a growing consensus that an insufficient supply of PDMP treatment products is a major safety risk to patients. Accordingly, it has been argued that a “vein-to-vein” approach to risk-based decision making that encompasses patient needs, product safety, ethical treatment of donors, and other ethical issues should be adopted when considering topics like PDMP donor compensation. In 2010, an International Consensus Conference on Risk-Based Decision Making for Blood Safety noted that, “As blood systems are focusing more on responsible use of health care resources, questions arise as to the most effective way to manage risk at a level that is tolerable and sustainable. Because of the increasing complexity and inconsistency in blood safety decision making, it is timely to explore whether it is possible to create a better decisionmaking framework based on risk management principles that can be used in various jurisdictions, taking into account social values, ethics, politics, economics, public expectations, and the historical context in which we operate.” In conducting the current analysis, we use these findings of the 2010 Consensus Conference and the subsequent framework developed by the ABO to integrate all stakeholder concerns into an overall risk profile to inform the decision-making process (the ABO Framework). In particular, we draw on the two elements of the framework most relevant to our analysis: the assessment component as a refresh of the ethical discussion around compensated plasma donation and the participation strategy for relevant stakeholder engagement that has been missing from past analyses of compensated plasma donation. We note that the economic considerations of compensation for PDMPs have been explored by Grabowski and Manning. In addition, we draw in part from the analytical structure of the Nuffield Council on Bioethics (Nuffield), which posed the question: How far can society go in its demands on people to act in what many regard as a good cause— that of providing bodily material to benefit others? The welfare of the many patients who do and could benefit from PDMPs is central to our analysis, and the welfare of donors is a powerful complementary consideration. There are notable distinctions between donor plasma destined for further manufacture into PDMPs and labile whole blood and its components (e.g., red blood cells